Human LRRC15 Stable Cell Line - CHO-K1

Adenoviruses for gene or oncolytic therapy, notably delivering the tumor suppressor p53, are in development. Researchers have investigated the use of adenoviruses for gene or oncolytic therapy, notably delivering the tumor suppressor p53. Despite advancements, limitations persist, prompting retroviral suppressor screens to identify resistance-conferring genes. LRRC15, a tumor antigen frequently overexpressed in various tumors, emerged as a suppressor of cell death induced by adenoviral p53. Interestingly, LRRC15 does not directly affect p53 function but rather impedes adenoviral infection by redistributing the coxsackievirus-adenovirus receptor away from the cell surface. This results in reduced adenoviral binding to LRRC15-expressing cells. This discovery not only enhances understanding of adenoviral biology but also holds significant implications for adenovirus-based anticancer therapeutics.

Figure 1. Researchers demonstrate that LRRC15 inhibits adenoviral attachment by conducting experiments with A549-LRRC15 and A549 control cells, incubating them with Ad-GFP on ice to allow attachment but not internalization. Subsequent staining and microscopy reveal reduced adenovirus binding in A549-LRRC15 cells compared to controls. (O'Prey J, et al., 2008)

Using Creative Biogene's Human LRRC15 Stable Cell Line - CHO-K1 enables more efficient investigation into LRRC15's role in inhibiting adenoviral attachment. Compared to the original method, this cell line offers a more reliable experimental model with higher stability and repeatability. Additionally, conducting experiments with LRRC15 stable cell lines saves time and resources while providing more accurate results.